INDP
NASDAQIndaptus Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.13-0.12 (-5.33%)
02:00 PM07:45 PM
News · 26 weeks380%
2025-12-072026-05-31
Mix1490d
- SEC Filings7(50%)
- Insider5(36%)
- Other1(7%)
- Leadership1(7%)
Latest news
25 items- SECSEC Form 10-Q filed by Indaptus Therapeutics Inc.10-Q - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- PRIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateNEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, "Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives. While this transition period involves certain operational and organizational adjustments, the Company remains focused on supporting and advancing its ther
- SECAmendment: Indaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- INSIDERSEC Form 3 filed by new insider Lu Qinglai3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Indaptus Therapeutics Inc.SCHEDULE 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- INSIDERSEC Form 3 filed by new insider Yao Yun3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sino Lion Ventures Ltd3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dai Junyi3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Changes in Control of Registrant, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- INSIDERSEC Form 4 filed by Lazar David E.4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- SECSEC Form 10-K filed by Indaptus Therapeutics Inc.10-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- INSIDERSEC Form 4 filed by Director Jabbour Jerome D4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- INSIDERSEC Form 3 filed by new insider Jabbour Jerome D3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- INSIDERNew insider Mcmurdo Matthew Charles claimed ownership of 25,000 shares (SEC Form 3)3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- INSIDERSEC Form 4 filed by Co-Chief Executive Officer Meckler Jeffrey A4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- SECSEC Form DEFA14A filed by Indaptus Therapeutics Inc.DEFA14A - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- INSIDERDirector Ben-Tzvi Avraham was granted 25,000 shares, increasing direct ownership by 25,000% to 25,100 units (SEC Form 4)4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- INSIDERSEC Form 4 filed by Director Natan David4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
- SECSEC Form DEF 14A filed by Indaptus Therapeutics Inc.DEF 14A - Indaptus Therapeutics, Inc. (0001857044) (Filer)
- SECIndaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
INDP FAQ
6 questionsWhat does Indaptus Therapeutics Inc. do?
Indaptus Therapeutics, Inc., a pre-clinical stage biotech company, develops a patented anti-cancer and antiviral immunotherapy. It engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases. The company's lead candidate is Decoy20 that is in pre-clinical stage to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. It also develops a proprietary platform that exploits bacteria's...Where does INDP stock trade?
Indaptus Therapeutics Inc. (INDP) is listed on NASDAQ.What sector and industry is INDP in?
Indaptus Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INDP?
Indaptus Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $1500.00 price target on 2022-01-31. Recent price targets range from $1500.00 to $1600.00.What companies are similar to INDP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INDP side-by-side with any of them on Quantisnow.How can I track INDP on Quantisnow?
Quantisnow aggregates Indaptus Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INDP to receive live email and push alerts on every new disclosure.